Novo Nordisk A/S ADR NVO

$37.82 -1.05 (-2.70%)

Valuation

Market cap
168,866,304,000
Revenue TTM
$46,792,290,000
Net income TTM
$15,508,510,000
P/E (trailing)
9.99
P/E (forward)
11.52
Profit margin
33.14%
Debt to equity
0.62

Trading

Volume
13,069,300
Avg volume
13,364,974
Day's range
$37.75 – $39.12
Shares out
4,465,000,000
Stochastic %K
2%
Beta
0.70
Analysts
Hold
Price target
$45.83

Price

Company profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare b...

Show more

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
45 44 44 88 88
Website
https://www.novonordisk.com
Address
Novo Alle 1, Bagsvaerd, Denmark

Latest news

Stocktwits

Pseudominds Nov 22, 6:13 AM
$NVO am I the only one here still super optimistic about novo? 😂 least bit of worry for me. A good company take time for market to adjust the share price. I have been thru it many times. Vote with your money :)
1 replies
Swimmingincash Nov 22, 3:44 AM
$NVO CEO sucks so bad. Why is he still around!!?
0 replies
MStocktwit Nov 22, 2:58 AM
$NVO $LLY European Medicines Agency flags concerns about Mounjaro and oral contraceptives https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026?utm_source
0 replies
Trendrebel Nov 22, 12:27 AM
$NVO I'm long here, but even if the market will recover, it will be a slow motion here. Now too many stocks are dirt cheap, and much cheaper than Novo with valuation around x2-4. This is where money will move into.
0 replies
macrossluvsrobotech Nov 21, 8:52 PM
$LXRX Why Nov 9 is huge for Q1 2027—in plain English: Lexicon’s pill (sotagliflozin) was already tested in 20,000 patients with heart failure, diabetes & kidney disease. Stiff, high-pressure heart failure acts a lot like HCM (thickened heart muscle) same pressure buildup & energy strain. 2 new lab studies from Chicago’s AHA heart conference (Nov 6–9) back this up in real human tissue & blood: • UPenn (PA—Rebecca Taichman & Dr. Sharlene Day, trial co-chair): Tested 120 living slices of human heart muscle from 32 people (16 HCM surgery patients + 16 non-failing donors) on tiny force sensors. Sotagliflozin quickly eased overworked muscle—beating rival empagliflozin at high pressure. • Mt. Sinai (Zafar et al.): 4-week study in 15 adults (400 mg sotagliflozin vs 10 mg empagliflozin)—sotagliflozin cut blood clots 11.9% (artery) & 15.6% (vein). Dual power: Flushes fluid/pressure (SGLT2) + works directly on heart muscle (SGLT1)—now focused on 542 HCM patients (Q1 2027)! $BIB $VTRS $NVO $BIB
0 replies
Snowyboy Nov 21, 8:18 PM
$NVO Almost any long on NOVO for last year's have lost money on NOVO unless you was able to escape. Bagholding NOVO is like the tornado sirens always roaring. Way undervalued and the first ever weight loss pill ever is what trapped me in the tornado. Been lost in this storm over year trapped from being up on profit and down never knowing when to sell how to catch the falling knife. Is this the the last days of this storm or will I be trapped forever.
0 replies
macrossluvsrobotech Nov 21, 5:27 PM
$LXRX First-principles science for Q1 2027: Across ~20,000 patients spanning every heart-adjacent malady under the sun—heart failure, diabetes, CKD, overweight & thrombosis—sotagliflozin 400 mg once daily cut broad CV/HF events by 30%—separates from placebo by Day 27–95. Now Phase 3 SONATA-HCM aims that exact 400 mg daily ceiling at ONE specific diagnosis with ZERO FDA-approved drugs: non-obstructive HCM (nHCM). Why zeroing in stacks the odds in our favor: • Less noise, sharper signal: Broad HF syndromes dilute drug effects across dozens of competing illnesses. Focusing 400 mg onto stiff, energy-starved nHCM (542 pts: 440 nHCM / 102 oHCM) concentrates the full biomechanical hit over 26 weeks. • Tri-organ 400 mg power: Kidneys (SGLT2) unload fluid/pressure; gut (SGLT1) smooths glucose & boosts GLP-1; heart muscle (direct SGLT1) aids relaxation, restores energy & cuts micro-clots. One simple daily pill (200, after 2 wks→ 400 mg), REMS-free, no CMI boxed warning. $BIB $VTRS $NVO $LLY
0 replies
inspector_gadget86 Nov 21, 4:11 PM 1 replies